Leukemia

Current research indicates that a rare but aggressive subtype of pediatric acute lymphoblastic leukemia (ALL) has surprisingly few mutations beyond the chromosomal rearrangement that affects the MLL gene.

Acute lymphoblastic leukemia (ALL) has been found to have two distinct subtypes, and evidence indicates that roughly 13% of ALL cases may be successfully treated with targeted drugs used in the treatment of lymphomas in adults.

Children with acute lymphoblastic leukemia with a certain gene variant experienced a higher incidence and severity of peripheral neuropathy after receiving treatment with the cancer drug vincristine, according to a study.

A tenth of patients with chronic lymphocytic leukemia (CLL) discontinued therapy with the Bruton tyrosine kinase inhibitor ibrutinib because of disease progression during clinical trials, according to a study.

A previously unrecognized action as a potent inhibitor of the dominant mutation that confers drug resistance to all well-tolerated treatments in patients with certain leukemia types has been found in Axitinib.

Among early-stage breast cancer patients who undergo chemotherapy and/or radiation treatment, the risk for developing treatment-related leukemia, though low, is still double what experts had previously thought.

By analyzing the DNA sequence of patients at different stages of leukemia, researchers have discovered mutations in genes that lead to childhood leukemia of the acute lymphoblastic type, the most common childhood cancer.

The EUROCARE study, the largest population-based study of survival in European blood cancer patients to date, analyzed data from 30 cancer registries, involving all patients with cancer diagnoses in 20 European countries.